Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Manchestertimes

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved…

Click here to view the original article.